R
Roldolfo Bordoni
Researcher at University of California, Los Angeles
Publications - 7
Citations - 1668
Roldolfo Bordoni is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 1645 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Alan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hillary Blacklock,Richard Bryan Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Rob Knight +16 more
TL;DR: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.
Journal ArticleDOI
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Amer M. Zeidan,Rachel J. Cook,Roldolfo Bordoni,James R. Berenson,William Jeffery Edenfield,Sanjay R. Mohan,Gongfu Zhou,Ekaterine Asatiani,Nithya Srinivas,Michael R. Savona +9 more
TL;DR: In this paper , a phase 1/2 study evaluated 2 oral, novel JAK1 inhibitors (INCB052793 and itacitinib) in advanced hematologic malignancies.
Journal ArticleDOI
451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors
Amanda Scott,Justin A. Call,Sreenivasa R Chandana,Erkut Borazanci,Gs. Falchook,Roldolfo Bordoni,Sarah Richey,Alexander Starodub,Vincent Chung,Nehal Lakhani,Elaine T. Lam,Kerry Schaffer,J.S. Wang,G. Shapiro,Jasgit C. Sachdev,Darrin M. Beaupre,Anthony W. Tolcher +16 more
TL;DR: CIRT as mentioned in this paper is a potent, selective pan CLK/DYRK inhibitor that modulates alternative splicing and is being evaluated in two ongoing phase I studies, a first in human (FIH) and combination trial.
Journal ArticleDOI
RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).
Kynan Feeney,Warren Joubert,Roldolfo Bordoni,Sunil Babu,S. Marimuthu,Bill Hipkin,Liping Huang,Rachel Tam,M. Acosta Rivera +8 more
TL;DR: The RELATIVITY-123 study as mentioned in this paper compared NIVO + RELA FDC with regorafenib or TAS-102 in adult patients with later lines of non-MSI-H/dMMR mCRC.